BR112022021691A2 - Moduladores de receptor de glicocorticoide (gr) para tratar um vírus sars-cov-2 - Google Patents

Moduladores de receptor de glicocorticoide (gr) para tratar um vírus sars-cov-2

Info

Publication number
BR112022021691A2
BR112022021691A2 BR112022021691A BR112022021691A BR112022021691A2 BR 112022021691 A2 BR112022021691 A2 BR 112022021691A2 BR 112022021691 A BR112022021691 A BR 112022021691A BR 112022021691 A BR112022021691 A BR 112022021691A BR 112022021691 A2 BR112022021691 A2 BR 112022021691A2
Authority
BR
Brazil
Prior art keywords
cov
sars
modulators
virus
treat
Prior art date
Application number
BR112022021691A
Other languages
English (en)
Portuguese (pt)
Inventor
Deisher Theresa
Wayne Mckay Scot
Original Assignee
Avm Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avm Biotechnology Llc filed Critical Avm Biotechnology Llc
Publication of BR112022021691A2 publication Critical patent/BR112022021691A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112022021691A 2020-04-29 2021-04-28 Moduladores de receptor de glicocorticoide (gr) para tratar um vírus sars-cov-2 BR112022021691A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017199P 2020-04-29 2020-04-29
PCT/US2021/029608 WO2021222385A1 (en) 2020-04-29 2021-04-28 Glucocorticoid receptor (gr) modulators for treating a sars-cov-2 virus

Publications (1)

Publication Number Publication Date
BR112022021691A2 true BR112022021691A2 (pt) 2022-12-20

Family

ID=76270026

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021691A BR112022021691A2 (pt) 2020-04-29 2021-04-28 Moduladores de receptor de glicocorticoide (gr) para tratar um vírus sars-cov-2

Country Status (7)

Country Link
US (1) US20230172950A1 (enExample)
EP (1) EP4142736A1 (enExample)
JP (1) JP2023524434A (enExample)
KR (1) KR20230015927A (enExample)
CN (1) CN115666583A (enExample)
BR (1) BR112022021691A2 (enExample)
WO (1) WO2021222385A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540319A (ja) * 2021-11-05 2024-10-31 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 肺粘膜炎症の処置のための低分子量ヒアルロン酸の使用
CN114028571B (zh) * 2021-11-18 2023-04-28 中国医学科学院基础医学研究所 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用
CN114099481B (zh) * 2022-01-28 2022-05-24 深圳湾实验室 雾化吸入型糖皮质激素纳米药物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3490605B1 (en) 2017-04-01 2023-06-07 AVM Biotechnology, LLC Replacement of cytotoxic preconditioning before cellular immunotherapy
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
CA3168378A1 (en) * 2020-02-28 2021-09-02 Avm Biotechnology, Llc Lypmphocyte population and methods for producing same

Also Published As

Publication number Publication date
CN115666583A (zh) 2023-01-31
KR20230015927A (ko) 2023-01-31
JP2023524434A (ja) 2023-06-12
WO2021222385A1 (en) 2021-11-04
US20230172950A1 (en) 2023-06-08
EP4142736A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
BR112022021691A2 (pt) Moduladores de receptor de glicocorticoide (gr) para tratar um vírus sars-cov-2
WO2019157366A8 (en) Antibody variable domains targeting the nkg2d receptor
JOP20210309A1 (ar) جزيئات ربط بـ cd19 واستخدامتها
EP4491234A3 (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
AU2018281308A1 (en) Methods and apparatuses for the thermal treatment of neurologic and psychiatric disorders
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
MX2022003193A (es) Tratamiento de encefalopatia asociada al gen syngap1.
CR20210335A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular la hemoglobina
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
BR112022026236A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr
BR112023020781A2 (pt) Moduladores de cbl-b e usos dos mesmos
MY178120A (en) Anti sez6 antibodies and methods of use
NO20091966L (no) Sammensetninger og fremgangsmater for a redusere proliferasjon av endometrie
WO2010111400A3 (en) Method and kits for treating appetite suppressing disorders and disorders with an increased metabolic rate
WO2019166412A9 (en) Modulation of pla2-g1b in therapy
MX2019005693A (es) Factor viii direccionado a los globulos rojos y metodo para su uso.
BR112022007179A2 (pt) Inibidores de tim-3 e usos dos mesmos
BR112018002524A2 (pt) modificação em catalisadores para controlar a arquitetura polimérica
BR112018073627A2 (pt) método para tratar câncer em um paciente
BR112021021787A2 (pt) Terapias de combinação
CO2023000114A2 (es) Composiciones y métodos para el tratamiento de enfermedades y trastornos usando vesículas extracelulares microbianas de oscillospiraceae
MX2025006565A (es) Terapia contra el cancer con capivasertib y fulvestrant
WO2016061320A3 (en) Timber therapy for post-traumatic stress disorder
BR112022021732A2 (pt) Tratamentos de câncer de próstata com combinações de acetato de abiraterona e niraparibe
BR112022010934A2 (pt) Métodos para tratar copd administrando um antagonista de il-33